Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.

Investigational new drugs - 1 Aug 2021

Pan Shouhua, Li Si, Xiao Mingzhe, Chen Dongsheng, Li Junlong

Abstract excerpt

Urothelial bladder cancer (UBC) is a common malignancy with considerable mortality worldwide. However, the treatment options of UBC are mainly chemotherapy and immunotherapy, as few targeted agents have demonstrated efficacy against UBC. In recent studies, everolimus has exhibited antitumor activity in patients harboring aberrations in the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/ mammalian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Everolimus

Share to Follow-Up Studies

Share to High-Throughput Nucleotide Sequencing

Share to Progression-Free Survival

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 33745098
DOI: 10.1007/s10637-021-01103-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.PMID 33745098Read ↗

Significant Benefit of Everolimus In a Patient With Urothelial Bladder Cancer Harboring A Rare M1043I Mutation of PIK3CASemantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.Semantic proximity Read ↗

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.Semantic proximity Read ↗

Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.Semantic proximity Read ↗

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.Semantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.Semantic proximity Read ↗

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.Semantic proximity Read ↗

Genome Sequencing Identifies a Basis for Everolimus SensitivitySemantic proximity Read ↗

TSC1 involvement in bladder cancer: diverse effects and therapeutic implicationsSemantic proximity Read ↗

Actionable mutations in muscle-invasive bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.